Phenotype-based screening rediscovered benzopyran-embedded microtubule inhibitors as anti-neuroinflammatory agents by modulating the tubulin–p65 interaction
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Neuroinflammation is one of the critical processes implicated in central nervous system (CNS) diseases. Therefore, alleviating neuroinflammation has been highlighted as a therapeutic strategy for treating CNS disorders. However, the complexity of neuroinflammatory processes and poor drug transport to the brain are considerable hurdles to the efficient control of neuroinflammation using small-molecule therapeutics. Thus, there is a significant demand for new chemical entities (NCEs) targeting neuroinflammation. Herein, we rediscovered benzopyran-embedded tubulin inhibitor 1 as an anti-neuroinflammatory agent via phenotype-based screening. A competitive photoaffinity labeling study revealed that compound 1 binds to tubulin at the colchicine-binding site. Structure–activity relationship analysis of 1’s analogs identified SB26019 as a lead compound with enhanced anti-neuroinflammatory efficacy. Mechanistic studies revealed that upregulation of the tubulin monomer was critical for the anti-neuroinflammatory activity of SB26019. We serendipitously found that the tubulin monomer recruits p65, inhibiting its translocation from the cytosol to the nucleus and blocking NF-κB-mediated inflammatory pathways. Further in vivo validation using a neuroinflammation mouse model demonstrated that SB26019 suppressed microglial activation by downregulating lba-1 and proinflammatory cytokines. Intraperitoneal administration of SB26019 showed its therapeutic potential as an NCE for successful anti-neuroinflammatory regulation. Along with the recent growing demands on tubulin modulators for treating various inflammatory diseases, our results suggest that colchicine-binding site-specific modulation of tubulins can be a potential strategy for preventing neuroinflammation and treating CNS diseases.
Abstract
Neuroinflammation is one of the critical processes implicated in central nervous system (CNS) diseases. Therefore, alleviating neuroinflammation has been highlighted as a therapeutic strategy for treating CNS disorders. However, the complexity of neuroinflammatory processes and poor drug transport to the brain are considerable hurdles to the efficient control of neuroinflammation using small-molecule therapeutics. Thus, there is a significant demand for new chemical entities (NCEs) targeting neuroinflammation. Herein, we rediscovered benzopyran-embedded tubulin inhibitor 1 as an anti-neuroinflammatory agent via phenotype-based screening. A competitive photoaffinity labeling study revealed that compound 1 binds to tubulin at the colchicine-binding site. Structure–activity relationship analysis of 1’s analogs identified SB26019 as a lead compound with enhanced anti-neuroinflammatory efficacy. Mechanistic studies revealed that upregulation of the tubulin monomer was critical for the anti-neuroinflammatory activity of SB26019. We serendipitously found that the tubulin monomer recruits p65, inhibiting its translocation from the cytosol to the nucleus and blocking NF-κB-mediated inflammatory pathways. Further in vivo validation using a neuroinflammation mouse model demonstrated that SB26019 suppressed microglial activation by downregulating lba-1 and proinflammatory cytokines. Intraperitoneal administration of SB26019 showed its therapeutic potential as an NCE for successful anti-neuroinflammatory regulation. Along with the recent growing demands on tubulin modulators for treating various inflammatory diseases, our results suggest that colchicine-binding site-specific modulation of tubulins can be a potential strategy for preventing neuroinflammation and treating CNS diseases.
참고문헌 (56)
- Chen, W. W., "Role of neuroinflammation in neurodegenerative diseases(Review)", Mol. Med. Rep, 13, pp.3391~3396 (2016)
- Kwon, H. S., "Neuroinflammation in neurodegenerative disorders : the roles of microglia and astrocytes", Transl. Neurodegener, 9, pp.42~ (2020)
- Leng, F., "Neuroinflammation and microglial activation in Alzheimer disease : where do we go from here? Nat", Rev. Neurol, 17, pp.157~172 (2021)
- Ransohoff, R. M., "How neuroinflammation contributes to neurodegeneration", Science, 353, pp.777~783 (2016)
- Block, M. L., "Microglia-mediated neurotoxicity : uncovering the molecular mechanisms", Nat. Rev. Neurosci, 8, pp.57~69 (2007)
- Streit, W. J., "Microglia and neuroinflammation : a pathological perspective", J. Neuroinflam, 1, pp.14~ (2004)
- Liddelow, S. A., "Neurotoxic reactive astrocytes are induced by activated microglia", Nature, 541, pp.481~487 (2017)
- Szepesi, Z., "Bidirectional microglia-neuron communication in health and disease", Front. Cell Neurosci, 12, pp.323~ (2018)
- Haruwaka, K., "Dual microglia effects on blood brain barrier permeability induced by systemic inflammation", Nat. Commun, 10, pp.5816~ (2019)
- Levey, A. I., "A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment", Brain, 145, pp.1924~1938 (2022)
- Lim, G. P., "Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease", J. Neurosci, 20, pp.5709~5714 (2000)
- Borre, Y., "Celecoxib delays cognitive decline in an animal model of neurodegeneration", Behav. Brain Res, 234, pp.285~291 (2012)
- Hung, S. Y., "Drug candidates in clinical trials for Alzheimer’s disease", J. Biomed. Sci, 24, pp.1~12 (2017)
- Underwood, D. C., "SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence", J. Pharmacol. Exp. Ther, 293, pp.281~288 (2000)
- Kumar, S., "p38 MAP kinases : key signalling molecules as therapeutic targets for inflammatory diseases", Nat. Rev. Drug Discov, 2, pp.717~726 (2003)
- Leister, K. P., "Two high throughput screen assays for measurement of TNF-αin THP-1 cells", Curr. Chem. Genom, 5, pp.21~29 (2011)
- Prins, N. D., "A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease", Alzheimer’s Res. Ther, 13, pp.1~12 (2021)
- Lin, S. T., "Tetrandrine suppresses LPS-induced astrocyte activation via modulating IKKs-IκBα-NF-κB signaling pathway", Mol. Cell. Biochem, 315, pp.41~49 (2008)
- He, F. Q., "Tetrandrine attenuates spatial memory impairment and hippocampal neuroinflammation via inhibiting NF-κB activation in a rat model of Alzheimer’s disease induced by amyloid-β(1–42)", Brain Res, 1384, pp.89~96 (2011)
- Combs, C. K., "Inflammatory mechanisms in Alzheimer’s disease : inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists", J. Neurosci, 20, pp.558~567 (2000)
- Grip, O., "Atorvastatin activates PPAR-γ and attenuates the inflammatory response in human monocytes", Inflamm. Res, 51, pp.58~62 (2002)
- Fu, W. Y., "Targeting neuroinflammation as a therapeutic strategy for Alzheimer’s disease : mechanisms, drug candidates, and new opportunities", ACS Chem. Neurosci, 10, pp.872~879 (2019)
- Costello, J. C., "Seeking the wisdom of crowds through challengebased competitions in biomedical research", Clin. Pharmacol. Ther, 93, pp.396~398 (2013)
- Swinney, D. C., "How were new medicines discovered?", Nat. Rev. Drug Discov, 10, pp.507~519 (2011)
- Croston, G. E., "The utility of target-based discovery", Expert Opin. Drug Discov, 12, pp.427~429 (2017)
- Joanne, K., "Phenotypic screening, take two", Sci. –Bus. Exch, 5, pp.380~ (2012)
- Park, J., "Discovery and target identification of an antiproliferative agent in live cells using fluorescence difference in two-dimensional gel electrophoresis", Angew. Chem. Int. Ed, 51, pp.5447~5451 (2012)
- Cocco, G., "Colchicine in clinical medicine. A guide for internists", Eur. J. Int. Med, 21, pp.503~508 (2010)
- Lennerz, C., "Colchicine for primary prevention of atrial fibrillation after open-heart surgery : systematic review and meta-analysis", Int. J. Cardiol, 249, pp.127~137 (2017)
- Deftereos, S. G., "Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019 : the GRECCO-19 randomized clinical trial", JAMA Netw. Open, 3, pp.e2013136~e2013136 (2020)
- Reyes, A. Z., "Anti-inflammatory therapy for COVID-19 infection : the case for colchicine", Ann. Rheum. Dis, 80, pp.550~557 (2021)
- Tardif, J. C., "Colchicine for community-treated patients with COVID-19(COLCORONA) : a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial", Lancet Respir. Med, 9, pp.924~932 (2021)
- Nidorf, S. M., "Low-dose colchicine for secondary prevention of cardiovascular disease", J. Am. Coll. Cardiol, 61, pp.404~410 (2013)
- Imazio, M., "Colchicine for acute and chronic coronary syndromes", Heart, 106, pp.1555~1560 (2020)
- Tardif, J. C., "Efficacy and safety of low-dose colchicine after myocardial infarction", N. Eng. J. Med, 381, pp.2497~2505 (2019)
- Nidorf, S. M., "Colchicine in patients with chronic coronary disease", N. Eng. J. Med, 383, pp.1838~1847 (2020)
- Robinson, K. P., "Colchicine in dermatology : a review", Australas. J. Dermatol, 59, pp.278~285 (2018)
- Weng, J. H., "Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation", Nat. Metab, 3, pp.513~522 (2021)
- Ousman, S. S., "Immune surveillance in the central nervous system", Nat. Neurosci, 15, pp.1096~1101 (2012)
- Kim, J., "Privileged structures : efficient chemical"navigators"toward unexplored biologically relevant chemical spaces", J. Am. Chem. Soc, 136, pp.14629~14638 (2014)
- Oh, S., "A design strategy for drug-like polyheterocycles with privileged substructures for discovery of specific small-molecule modulators", Chem. Commun, 47, pp.12754~12761 (2011)
- Dalbeth, N., "Mechanism of action of colchicine in the treatment of gout", Clin. Ther, 36, pp.1465~1479 (2014)
- De Vera, M., "Gout and the risk of Parkinson’s disease : a cohort study", Arthritis Rheum, 59, pp.1549~1554 (2008)
- Hong, J. Y., "Gout and the risk of dementia: a nationwide population-based cohort study", Arthritis Res. Ther, 17, pp.139~ (2015)
- Lu, N., "Gout and the risk of Alzheimer’s disease : a population-based, BMImatched cohort study", Ann. Rheum. Dis, 75, pp.547~551 (2016)
- Tan, C. S. H., "Thermal proximity coaggregation for system-wide profiling of protein complex dynamics in cells", Science, 359, pp.1170~1177 (2018)
- Langeback, A., "CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance", Sci. Rep, 9, pp.19384~ (2019)
- Liu, T., "NF-kappaB signaling in inflammation", Signal. Transduct. Target Ther, 2, pp.e17023~ (2017)
- Li, Z., "Inhibition of LPS-induced tumor necrosis factor-α production by colchicine and other microtubule disrupting drugs", Immunobiology, 195, pp.624~639 (1996)
- Jackman, R. W., "Microtubulemediated NF-kappaB activation in the TNF-alpha signaling pathway", Exp. Cell Res, 315, pp.3242~3249 (2009)
- Kappelmann-Fenzl, M., "Complex formation with monomeric alpha-tubulin and importin 13 fosters c-Jun protein stability and is required for c-Jun’s nuclear translocation and activity", Cancers, 11, pp.1806~ (2019)
- Viatour, P., "Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation", Trends Biochem. Sci, 30, pp.43~52 (2005)
- Qaseem, A., "Management of acute and recurrent gout : a clinical practice guideline from the American College of Physicians", Ann. Int. Med, 166, pp.58~68 (2017)
- Dasgeb, B., "Colchicine : an ancient drug with novel applications", Br. J. Dermatol, 178, pp.350~356 (2018)
- Rai, A., "Transcription factor NF-κB associates with microtubules and stimulates apoptosis in response to suppression of microtubule dynamics in MCF-7 cells", Biochem. Pharmacol, 93, pp.277~289 (2015)
- Shekelle, P. G., "Management of gout: a systematic review in support of an American College of Physicians clinical practice guideline", Ann. Intern. Med, 166, pp.37~51 (2017)